Zenicor Medical Systems Ab · NGM:ZENI
Zenicor Medical Systems Ab — Investor Presentation (October 2025)
11 slides from Zenicor Medical Systems Ab's investor presentation, October 2025
Slide 1: Zenicor Medical Systems AB (publ) Company Presentation 2025
Zenicor Medical Systems AB (publ) Company Presentation 2025 www.zenicor.se
Slide 2: Zenicor – A well-established European medtech company positioned for growth
Zenicor – A well-established European medtech company positioned for growth • Currently a market leader, providing ECG assessment systems for early diagnosis of cardiac arrhythmias and stroke prevention, with a focus on the professional healthcare sector • Offering cost-efficient, clinically validat
Slide 3: Every day, 1 000 people in Europe suffer a stroke due to atrial fibrillation
Every day, 1 000 people in Europe suffer a stroke due to atrial fibrillation Zenicor’s mission is to become a world leader in cardiac arrhythmia diagnostics for professional care 3
Slide 4: Quote from founder and CEO of Zenicor; Steady organic growth
Quote from founder and Steady organic growth CEO of Zenicor over the years From press release 29 September 2025 in connection with new share issue1 Net Sales “We are very grateful for the trust and support we receive from our existing owners, SEKm and we also welcome new investors. Zenicor’s product
Slide 5: The Zenicor Solution
The Zenicor Solution Zenicor ONE is used in the world’s largest atrial fibrillation screening study (SAFER) in the UK, with over 23,000 participants screened – strengthening clinical evidence and future growth potential ahead of the study’s final results in 2028 Zenicor’s business model is based on
Slide 6: A complete system for arrhythmia assessment (MDR certified)
A complete system for arrhythmia assessment (MDR certified) Zenicor ONE Zenicor One is a handheld ECG device where patient’s ECG is simply recorded by placing thumbs on two electrodes for 30 seconds. The simple method allows for a prolonged investigation period, during which the patient records thei
Slide 7: Early diagnosis - Scientifically Validated, Clinically Proven
Early diagnosis - Scientifically Validated, Clinically Proven EARLY DIAGNOSIS IN RISK PATIENTS Scan QR code to ● Key findings from studies: read more about the science behind SYMPTOMATIC o High diagnostic yield Zenicor ASYMPTOMATIC o Stroke prevention impact o Scalable screening ARRHYTHMIA PREVENTIV
Slide 8: Customer case: Region Värmland - integrated care pathway for early diagnosis
Customer case: Region Värmland - integrated care pathway for early diagnosis Back-end system supporting different products and services Region Värmland was the first to implement Zenicor-ECG in primary care and has been using it across the entire region since 2018. Zenicor enables more efficient dia
Slide 9: Screening for atrial fibrillation in risk population
Screening for atrial fibrillation in risk population ● Zenicor is the sole supplier in some of the most prominent studies for atrial fibrillation screening o SAFER study in the UK, is the world’s largest randomised controlled AF study with first analysis of data mid-2025 and results 2028 - Cambridge
Slide 10: Market Strategy 2025/2026
Market Strategy 2025/2026 ● Delivery of the newly won deals based on Zenicor Solution o Tender won in Region of Dalarna o Signed frame agreement with Doktor.se primary care units ● Focus on core markets: Sweden, Finland, and the UK in 2025/2026 o New tenders and regions in Sweden and Finland o Hospi
Slide 11: Zenicor Medical Systems AB (publ)
Zenicor Medical Systems AB (publ) Org no. 556642-3678 Saltmätargatan 8 113 59 Stockholm www.zenicor.se
Zenicor Medical Systems — Investor Presentation (October 2025) on 6ix